Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec Achieves Sanofi Diabetes Milestone | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Evotec Achieves Sanofi Diabetes Milestone

Achieves preclinical proof-of-concept, triggering €3.0 million payment

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec has achieved preclinical proof-of-concept in its strategic alliance with Sanofi in the field of diabetes, triggering a €3.0 million milestone payment to Evotec.

Evotec and Sanofi signed their collaboration in August 2015 with the goal of developing a beta cell replacement therapy based on functional beta cells derived from human stem cells. In addition, the companies aim to use human beta cells for high-throughput drug screening to identify small molecules or biologics beneficial for beta cell activity.

Dr. Cord Dohrmann, chief scientific officer of Evotec, said, “Diabetes represents one of the major threats to global healthcare systems and we are committed to discover new treatment options together with our colleagues at Sanofi. We are very pleased to have achieved this very important milestone that represents a major step forward towards developing a new therapeutic option for diabetes patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics